Tobira Therapeutics
TBRA

From December 31, 2014 to December 31, 2015 Conversion of Series A and B convertible preferred stock to common stock Conversion of convertible notes and accrued interest to common stock Issuance of shares in connection with Merger Conversion of Series F preferred stock assumed in Merger to common stock Issuance of shares to financial advisors in connection with Merger Issuance of shares for cash, net of issuance costs of $174 Issuance of shares at-the-market, net of issuance costs of $642 Issuance of shares from stock options exercised All numbers described in this Proposal Three have been adjusted to reflect the 1-for-9 reverse split of our common stock effected on May 4, 2015 in connection with the closing of the merger.

from December 31, 2014 to June 30, 2015 Conversion of convertible notes and accrued interest Conversion of Series A and B preferred stock Issuance of shares in connection with the Merger Issuance of shares for banker fees Issuance of shares in connection with the Private Placement Conversion of Series F preferred stock On May 4, 2015, Regado effected a one for nine reverse stock split of its outstanding common stock and options for common stock.

All numbers described in this Proposal Three have been adjusted to reflect the 1-for-9 reverse split of our common stock effected on May 4, 2015 in connection with the closing of the merger.

On May 4, 2015, Regado effected a one for nine reverse stock split of its outstanding common stock and options for common stock.

from December 31, 2013 to June 30, 2014 Issuance of common stock from private placement offering, net of issuance costs and placement fees of $1.4M Issuance of common stock upon public offering, net of issuance costs of $4.2M Issuance of common stock from exercise of options Issuance of common stock from exercise of warrants Exchange of common stock for Series F preferred stock Exchange of common stock for Series F preferred stock, adjustments to net issuance costs

from December 31, 2012 to November 7, 2013 Issuance of common stock upon initial public offering, net of underwriting discounts and offering costs of $5,611 Issuance of common stock upon exercise of warrants Issuance of common stock upon exercise of options Issuance of Series E Preferred stock, net of issuance costs of $147 In May 2013, our board of directors and our stockholders approved an amendment to the amended and restated certificate of incorporation to effect a one-for-16.7 reverse split of shares of common stock and to increase the number of authorized shares of common stock to 500,000,000, each of which was effected on May 21, 2013.

a one-for-16.7 reverse split of our common stock and an increase in the number of shares of common stock we are authorized to issue to 500,000,000, each of which became effective on May 21, 2013;the conversion of our outstanding shares of preferred stock into an aggregate of 9,396,767 shares of our common stock immediately prior to the closing of this offering;

from December 31, 2012 to June 30, 2013 Exercise of common stock warrants Stock compensation

from December 31, 2012 to May 22, 2013 Issuance of Series E Preferred stock, net of issuance costs of $50 a one-for-16.7 reverse split of our common stock and an increase in the number of shares of common stock we are authorized to issue to 500,000,000, each of which became effective on May 21, 2013

from December 31, 2012 to March 31, 2013 Issuance of Series E Preferred stock, net of issuance costs of $50

from December 31, 2011 to December 31, 2012 Issuance of Series E Preferred Stock, net of issuance costs of $466